Skip to content

A randomised controlled trial comparing endometrial ablation plus levonorgestrel releasing intrauterine system versus endometrial ablation alone in women with heavy menstrual bleeding (MIRA 2 trial).

A randomised controlled trial comparing endometrial ablation plus levonorgestrel releasing intrauterine system versus endometrial ablation alone in women with heavy menstrual bleeding (MIRA 2 trial). - MIRA 2 trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON54839
Enrollment
718
Registered
2019-04-18
Start date
2019-11-19
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heavy menstrual bleeding, dysmenorrhoea Heavy menstrual bleeding, dysmenorrhoea

Interventions

Endometrial ablation and LNG-IUS combined, control group is standard care with&nbsp
only an endometrial ablation.

Sponsors

Máxima MC
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Women suffering from heavy menstrual bleeding, who opt for treatment with EA, irrespective of the existence of fibroids, polyps or adenomyosis.

Exclusion criteria

Exclusion criteria: - Women who don't speak Dutch or English to a standard that they can fully understand the study and complete the trial questionnaires. - Women with a (future) childwish - Women with a suspicion on endometrial cancer. - Women with contra-indications for levonorgestrel IUD. - Women with an already performed Endometrial Ablation.  - Women over 60 years old.

Design outcomes

Primary

MeasureTime frame
Primary: hysterectomy rate after 2 years of follow-up.

Secondary

MeasureTime frame
Patient satisfaction, PBAC-score, quality of life, cyclisch and non-cyclic pelvic pain, side-effects, re-interventions, complications and cost-effectiveness.

Countries

Netherlands

Contacts

Public ContactTJ Oderkerk

Máxima MC

tamara.oderkerk@mmc.nl040 888 8000

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jul 3, 2026